Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birch pollen sublingual immunotherapy for birch pollen-induced rhinoconjunctivitis
2010-020693-42Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Aug 2010
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and birch pollen allergy comparing Birch Pollen Allergen Extract 300 IR with Placebo (2 arms). Primary endpoint: Average Adjusted Symptom Score. Started Aug 2010; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinoconjunctivitis (ARC)birch pollen allergy
Beyond the preview
Go deeper on 2010-020693-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020693-42.